An antibody binding to human XCR1, wherein the antibody is: the antibody comprising a heavy chain variable region comprising heavy chain CDRs 1 to 3 described in (g) to (i) below and a light chain variable region comprising light chain CDRs 1 to 3 described in (j) to below; the antibody comprising a heavy chain variable region comprising heavy chain CDRs 1 to 3 described in (m) to (o) below and a light chain variable region comprising light chain CDRs 1 to 3 described in (p) to (r) below; or the antibody comprising a heavy chain variable region comprising heavy chain CDRs 1 to 3 described in (a) to (c) below and a light chain variable region comprising light chain CDRs 1 to 3 described in (d) to (f) below: (a) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 41, (b) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 42, (c) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 43; (d) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 44, (e) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 45, and (f) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 46; (g) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 17, (h) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 18, (i) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 19; (j) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 20, (k) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 21, (l) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 22; (m) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 29, (n) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 30, (o) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 31; (p) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 32, (q) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 33, and (r) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 34. the antibody comprising a heavy chain variable region comprising heavy chain CDRs 1 to 3 described in (g) to (i) below and a light chain variable region comprising light chain CDRs 1 to 3 described in (j) to below; the antibody comprising a heavy chain variable region comprising heavy chain CDRs 1 to 3 described in (m) to (o) below and a light chain variable region comprising light chain CDRs 1 to 3 described in (p) to (r) below; or the antibody comprising a heavy chain variable region comprising heavy chain CDRs 1 to 3 described in (a) to (c) below and a light chain variable region comprising light chain CDRs 1 to 3 described in (d) to (f) below: (a) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 41, (b) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 42, (c) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 43; (d) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 44, (e) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 45, and (f) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 46; (g) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 17, (h) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 18, (i) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 19; (j) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 20, (k) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 21, (l) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 22; (m) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 29, (n) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 30, (o) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 31; (p) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 32, (q) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 33, and (r) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 34. (a) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 41, (b) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 42, (c) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 43; (d) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 44, (e) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 45, and (f) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 46; (g) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 17, (h) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 18, (i) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 19; (j) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 20, (k) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 21, (l) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 22; (m) a heavy chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 29, (n) a heavy chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 30, (o) a heavy chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 31; (p) a light chain CDR 1 consisting of the amino acid sequence of SEQ ID NO: 32, (q) a light chain CDR 2 consisting of the amino acid sequence of SEQ ID NO: 33, and (r) a light chain CDR 3 consisting of the amino acid sequence of SEQ ID NO: 34.